Metraipolis › archive › dc_ed986374cec2

Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL) — Europe PMC PMID:42127092

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42127092
DOI
10.1371/journal.pone.0342702
License (as archived)
solo-consultazione
Archived
2026-10-08T06:59:43.637Z
SHA-256 of the archived text
4187d3e34b59a9347fc8517c20fe127c0cfd5b6ed8191823cec40b56cc9f8f7e
Stable URL of this page
https://metraipolis.com/documento/dc_ed986374cec2

How to cite

Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL) — Europe PMC PMID:42127092 — Europe PMC (en), https://europepmc.org/article/MED/42127092 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ed986374cec2 (Metraipolis archive dc_ed986374cec2, sha256 4187d3e34b59a9347fc8517c20fe127c0cfd5b6ed8191823cec40b56cc9f8f7e)
BibTeX
@misc{dced986374cec2,
  title = {Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL) — Europe PMC PMID:42127092},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42127092},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ed986374cec2; sha256 4187d3e34b59a9347fc8517c20fe127c0cfd5b6ed8191823cec40b56cc9f8f7e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42127092. Agents can read the archived copy with the MCP tool read_document.